Similar articles for PMID: 35641290

Year	Number of Results
2008	4
2009	1
2010	1
2011	1
2012	3
2014	2
2015	6
2016	10
2017	11
2018	8
2019	11
2020	20
2021	35
2022	27
2023	8
2024	0

1

Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.

Tachibana H, Inakawa T, Nemoto Y, Ishihara H, Fukuda H, Yoshida K, Iizuka J, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Tachibana H, et al. Anticancer Res. 2022 Jun;42(6):3151-3158. doi: 10.21873/anticanres.15804. Anticancer Res. 2022. PMID: 35641290

2

Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.

Riveros C, Ranganathan S, Xu J, Chang C, Kaushik D, Morgan M, Miles BJ, Muhammad T, Anis M, Aghazadeh M, Zhang J, Efstathiou E, Klaassen Z, Brooks MA, Rini B, Wallis CJD, Satkunasivam R. Riveros C, et al. Urol Oncol. 2023 Mar;41(3):150.e1-150.e9. doi: 10.1016/j.urolonc.2022.11.022. Epub 2023 Jan 5. Urol Oncol. 2023. PMID: 36610815

3

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.

de Vries-Brilland M, Gross-Goupil M, Seegers V, Boughalem E, Beuselinck B, Thibault C, Chevreau C, Ladoire S, Barthélémy P, Negrier S, Borchiellini D, Huillard O, Geoffrois L, Gravis G, Saldana C, Thiery-Vuillemin A, Escudier B, Ravaud A, Albiges L. de Vries-Brilland M, et al. Eur J Cancer. 2020 Sep;136:76-83. doi: 10.1016/j.ejca.2020.02.019. Epub 2020 Jul 9. Eur J Cancer. 2020. PMID: 32653774

4

Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.

McGregor BA, Lalani AA, Xie W, Steinharter JA, E Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, Choueiri TK. McGregor BA, et al. Eur J Cancer. 2020 Aug;135:203-210. doi: 10.1016/j.ejca.2020.05.009. Epub 2020 Jun 27. Eur J Cancer. 2020. PMID: 32599410

5

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.

Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Campbell MT, et al. Eur J Cancer. 2018 Nov;104:188-194. doi: 10.1016/j.ejca.2018.08.014. Epub 2018 Oct 28. Eur J Cancer. 2018. PMID: 30380460

6

Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.

Yoo S, You D, Jeong IG, Song C, Hong B, Hong JH, Ahn H, Kim CS. Yoo S, et al. J Cancer Res Clin Oncol. 2017 Sep;143(9):1845-1851. doi: 10.1007/s00432-017-2430-6. Epub 2017 Apr 27. J Cancer Res Clin Oncol. 2017. PMID: 28451753

7

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.

Zhao H, Nolley R, Chan AMW, Rankin EB, Peehl DM. Zhao H, et al. Cancer Biol Ther. 2017 Nov 2;18(11):863-871. doi: 10.1080/15384047.2016.1219816. Epub 2016 Aug 11. Cancer Biol Ther. 2017. PMID: 27715452 Free PMC article.

8

Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.

Tirumani SH, Souza D, Krajewski KM, Jagannathan JP, Ramaiya NH, Shinagare AB. Tirumani SH, et al. Abdom Radiol (NY). 2016 Feb;41(2):295-302. doi: 10.1007/s00261-015-0569-7. Abdom Radiol (NY). 2016. PMID: 26867911

9

Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.

Kaldany A, Paulucci DJ, Kannappan M, Beksac AT, Anastos H, Okhawere K, Sfakianos JP, Badani KK. Kaldany A, et al. Urol Oncol. 2019 Oct;37(10):727-734. doi: 10.1016/j.urolonc.2019.05.008. Epub 2019 Jun 5. Urol Oncol. 2019. PMID: 31174958

10

Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.

Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Iacovelli R, et al. Target Oncol. 2020 Aug;15(4):495-501. doi: 10.1007/s11523-020-00732-y. Target Oncol. 2020. PMID: 32671807

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

124 results

Results by year